Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
Phase 2
Terminated
- Conditions
- Vasospasm
- Interventions
- Drug: Cervical Sympathetic Block (bupivicaine, clonidine)
- Registration Number
- NCT00930072
- Lead Sponsor
- University of Washington
- Brief Summary
To evaluate the feasibility of performing a cervical sympathetic block in patients with severe cerebral vasospasm involving the anterior cerebral circulation following aneurysmal SAH.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 7
Inclusion Criteria
- High grade spontaneous SAH (Fisher Grade III and IV)
- Secured aneurysm (clipped/coiled)
- Evidence of severe vasospasm - MCA mean flow velocity >200 cm/sec and Lindegaard ratio >6 OR Symptomatic vasospasm with either angiographic evidence (no angioplasty), or at least moderate severity according to TCD criteria (MCA mean flow velocity >150 cm/sec and Lindegaard ratio >3, or ACA vasospasm)
- Age ≥18
Read More
Exclusion Criteria
- Allergy to local anesthetic or contrast
- Coagulation disorders with PT <70%, or INR >1.4, or PTT >1.5 times control and/or platelets <70,000x106/L
- Use of enoxaparin within 12 hours
- Use of clopidogrel within 7 days
- Use of coumadin within 5 days
- Use of ticlopidine within 14 days
- Use of intravenous thrombolytics within 10 days
- Any use of hirudin derivatives during ICU stay
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Block Cervical Sympathetic Block (bupivicaine, clonidine) -
- Primary Outcome Measures
Name Time Method To evaluate the feasibility of performing a cervical sympathetic block in patients with severe cerebral vasospasm involving the anterior cerebral circulation following aneurysmal SAH. 3 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Harborview Medical Center
🇺🇸Seattle, Washington, United States